SEARCH:   Advanced

Blood, 15 December 2007, Vol. 110, No. 13, pp. 4552-4559. Prepublished online as a Blood First Edition Paper on August 23, 2007; DOI 10.1182/blood-2007-06-093880. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-06-093880v1 110/13/4552    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Jakubowski, A. A. Articles by Papadopoulos, E. B. Search for Related Content PubMed PubMed Citation Articles by Jakubowski, A. A. Articles by Papadopoulos, E. B. Related Collections Immunobiology Transplantation Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION T cell–depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin Ann A. Jakubowski1, Trudy N. Small2, James W. Young1, Nancy A. Kernan2, Hugo Castro-Malaspina1, Katherine C. Hsu1, Miguel-Angel Perales1, Nancy Collins3, Christine Cisek2, Michelle Chiu2, Marcel R. M. van den Brink1, Richard J. O'Reilly2, and Esperanza B. Papadopoulos1 1 Adult Allogeneic Bone Marrow Transplant Service, Division of Hematologic-Oncology, Department of Medicine; 2 Department of Pediatrics; and 3 Department of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY Antithymocyte globulin (ATG) has been used in allogeneic stem-cell transplantation to prevent graft rejection and graft-versus-host disease (GvHD). Its use, however, has been associated with delayed T-cell reconstitution and prolonged susceptibility to opportunistic infections (OIs) especially in patients undergoing T cell–depleted (TCD) transplantation. Recently, a prospective trial was conducted in 52 adult patients (median age, 47 years) with various hematologic malignancies undergoing TCD transplantation from HLA-matched related donors without the use of ATG. The cytoreductive regimen consisted of hyperfractionated total body irradiation (HFTBI), thiotepa, and fludarabine. The preferred source of the graft was peripheral blood stem cells (PBSCs). No additional graft rejection or GvHD prophylaxis was given. All evaluable patients engrafted without any immune-mediated graft rejections. Disease-free survival (DFS) at 3 years was 61% in all patients, and 70% in patients with standard-risk disease. Acute GvHD was limited to grade 2 in 8% and chronic GvHD in 9% of patients. Life-threatening OIs occurred in 3 of 52 patients and was fatal in 1. This study demonstrates durable engraftment with a low incidence of GvHD despite the lack of ATG, as well as the curative potential of this regimen. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. E. Kohrt, B. B. Turnbull, K. Heydari, J. A. Shizuru, G. G. Laport, D. B. Miklos, L. J. Johnston, S. Arai, W.-K. Weng, R. T. Hoppe, et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors Blood, July 30, 2009; 114(5): 1099 - 1109. [Abstract] [Full Text] [PDF] O. Landgren, E. S. Gilbert, J. D. Rizzo, G. Socie, P. M. Banks, K. A. Sobocinski, M. M. Horowitz, E. S. Jaffe, D. W. Kingma, L. B. Travis, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation Blood, May 14, 2009; 113(20): 4992 - 5001. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020